Screener
Rhythm Pharmaceuticals, Inc. RYTM Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value |
|---|---|---|---|---|
| Assets | ||||
| Corporate debt securities and commercial paper (due within 1 year) | $217,812 | $66 | $(104) | $217,774 |
| U.S. Treasury Securities | 60,620 | 102 | (8) | 60,714 |
| $278,432 | $168 | $(112) | $278,488 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s cumulative cost basis?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported cumulative cost basis of $278.43M in Q1 2026.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude